Lorazepam Injection shortage
Lorazepam Injection is currently listed in shortage by the FDA. The FDA lists 11 affected products. The reported reason: Other; Demand increase for the drug. This page was last refreshed from FDA data on Sep 25, 2026.
The 4 mg/1 mL strength of lorazepam injection has no available source right now, while the 2 mg/1 mL strength remains listed by several manufacturers. The 4 mg/mL strength is listed by some makers not currently reporting a shortage, so supply may exist, but availability is limited and this shortage has lasted over a year.
Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers (see options) and your prescriber about a long-term plan.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Lorazepam Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 22, 2026Currently in shortage11 of 11 products affected.
-
Sep 18, 2026FDA refreshed this shortage record8 products updated.
-
Sep 16, 2026FDA refreshed this shortage record1 product updated.
-
Sep 15, 2026FDA refreshed this shortage record1 product updated.
-
Sep 5, 2018More presentations reported7 more products added to the shortage.
-
May 3, 2018First reported to the FDA4 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Amphastar Pharmaceuticals, Inc. 📞 800-423-4136 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1) | — | Available | — | — |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02) | — | Unavailable | Next release September 2026. Check wholesalers for inventory. | Demand increase for the drug |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 8 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10) | — | Unavailable | Estimated recovery: TBD | Other |
| Current | Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25) | — | Limited Availability | Estimated recovery: TBD | Demand increase for the drug |
| Current | Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10) | — | Unavailable | Estimated recovery: TBD | Other |
| Current | Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10) | — | Unavailable | Estimated recovery: TBD | Other |
| Current | Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25) | — | Unavailable | Estimated recovery: TBD | Other |
| Current | Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25) | — | Unavailable | Estimated recovery: TBD | Other |
| Current | Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25) | — | Limited Availability | Estimated recovery: TBD | Demand increase for the drug |
| Current | Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10) | — | Unavailable | Estimated recovery: TBD | Other |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30) | — | Limited Availability | Limited Supply Available. Next Delivery: July 2027; Estimated Recovery: September 2027 | Demand increase for the drug |
These rows are manufacturer reports to the FDA for Lorazepam Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Lorazepam Injection? options further down this page.
Why is Lorazepam Injection in shortage?
The main reason lorazepam injection is on the shortage list is that more people need it than the current supply can keep up with — and for some manufacturers, there are additional unspecified issues they haven't made public. Looking at the specifics: Hikma has most of its 2 mg/mL and 4 mg/mL vials either completely unavailable or in very limited supply, with no firm recovery date set yet. Fresenius Kabi's 2 mg/mL vials are currently unavailable, with the next expected release around September 2026 (checking wholesalers may turn up some remaining stock). Hospira/Pfizer has their 2 mg/mL prefilled syringes in limited supply, with the next delivery expected July 2027 and a fuller recovery estimated around September 2027.
It's worth knowing that not every product in this report is affected the same way — Amphastar's 2 mg/mL lorazepam injection is currently listed as available. Also, this report only covers these specific manufacturers and their particular package sizes, so the picture across the entire market may look different than what's described here.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Lorazepam Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Lorazepam Injection?
Lorazepam injection is currently on the FDA shortage list, and I want to walk you through what that means for the strength you use.
The affected strengths differ. The 2 mg/1 mL solution still has an available source, and the 2 mg/1 mL syringes are reported in limited supply. The 4 mg/1 mL strength currently has no available source from the manufacturers on this record.
This shortage has been ongoing for over a year, and the reported reasons are an increase in demand along with "other" factors. Three of the four manufacturers on this record are still reporting some supply, so this reflects only the makers who filed — not every company that produces this medicine. Recovery timelines are listed as "to be determined," with some restocking dates noted later in 2026 and 2027.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- If you use the 2 mg/1 mL, ask your pharmacy to order it — they can check wholesalers and other manufacturers, including Amphastar, which reports it as available.
- The same medicine is also listed from other makers (Hikma, Fresenius Kabi, Civica, and RemedyRepack); your pharmacy may be able to source one, though it may not be in local stock.
- If your exact strength cannot be found, ask your prescriber or pharmacist about safe options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
- This is a controlled substance. Transfers between pharmacies and switching strengths have extra federal/state rules — ask the pharmacy before you assume a transfer is possible.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Lorazepam Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Lorazepam Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Lorazepam | LORAZEPAM 2 mg/mL | Injection · Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 00641-6048-25 |
| Lorazepam | LORAZEPAM 4 mg/mL | Injection · Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 00641-6049-25 |
| Lorazepam | LORAZEPAM 2 mg/mL | Injection · Intramuscular, Intravenous | Fresenius Kabi USA, LLC | 65219-0368-24 |
| Lorazepam | LORAZEPAM 2 mg/mL | Injection, Solution · Intramuscular, Intravenous | REMEDYREPACK INC. | 70518-3766-00 |
| Lorazepam | LORAZEPAM 2 mg/mL | Injection · Intramuscular, Intravenous | Civica, Inc. | 72572-0380-25 |
Alternative dosage forms of Lorazepam
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 13 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Lorazepam 2 mg/mL | Hikma | 25 vials | $2.172 | AP | Availability likely |
| Lorazepam 2 mg/mL | Civica, | 25 vials | $2.172 | AP | Availability likely |
| Lorazepam 2 mg/mL | Hikma | 25 vials | $2.172 | AP | Availability likely |
| Lorazepam 2 mg/mL | Hikma | 25 vials | $2.172 | AP | Availability likely |
| Lorazepam 2 mg/mL | Fresenius | 25 vials | $2.172 | AP | Availability likely |
| Ativan 2 mg/mL | Hikma | 10 vials | — | AP | FDA listed |
| Lorazepam 2 mg/mL | Hikma | 10 vials | — | AP | FDA listed |
| Lorazepam 2 mg/mL | Hikma | 10 vials | — | AP | FDA listed |
| Lorazepam 2 mg/mL | International | 10 vials | — | AP | FDA listed |
| Lorazepam 2 mg/mL | Hospira, | 10 cartridges | — | AP | FDA listed |
| Ativan 2 mg/mL | Hikma | 25 vials | — | AP | FDA listed |
| Lorazepam 2 mg/mL | Fresenius | 25 vials | — | AP | FDA listed |
| Lorazepam 2 mg/mL | REMEDYREPACK | 10 cartridges | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Lorazepam Injection — that fall in the same broad treatment class (sedative-hypnotics - benzodiazepines) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other neurology shortages
Lorazepam Injection shortage FAQs
Is Lorazepam Injection in shortage?
Why is Lorazepam Injection in shortage?
Which products are affected?
When will Lorazepam Injection be available again?
Can I still get Lorazepam somewhere?
What should I do if I take Lorazepam Injection?
Still have a question about the Lorazepam Injection shortage?
Ask a pharmacist about this shortage →View Lorazepam Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.